Have a feature idea you'd love to see implemented?
Let us know!
PBYI Puma Biotechnology Inc
Price (delayed)
$3.1
Market cap
$152.17M
P/E Ratio
6.46
Dividend/share
N/A
EPS
$0.48
Enterprise value
$171.28M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
Highlights
The net income has soared by 167% from the previous quarter
PBYI's EPS has surged by 153% since the previous quarter
Puma Biotechnology's quick ratio has decreased by 19% YoY but it has increased by 14% from the previous quarter
PBYI's gross profit is up by 5% QoQ but it is down by 3% YoY
Puma Biotechnology's gross margin has decreased by 9% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of PBYI
Market
Valuations
Earnings
Shares outstanding
49.09M
Market cap
$152.17M
Enterprise value
$171.28M
Price to book (P/B)
2.14
Price to sales (P/S)
0.62
EV/EBIT
4.53
EV/EBITDA
3.47
EV/Sales
0.7
Revenue
$243.57M
Gross profit
$168.76M
Net income
$23.24M
EBIT
$37.85M
EBITDA
$49.42M
Free cash flow
$33.68M
Per share
Balance sheet
Liquidity
EPS
$0.48
EPS diluted
$0.47
Free cash flow per share
$0.69
Book value per share
$1.45
Revenue per share
$4.97
TBVPS
$3.41
Total assets
$220.72M
Total liabilities
$149.63M
Debt
$86.37M
Equity
$71.09M
Working capital
$46.42M
Debt to equity
1.21
Current ratio
1.42
Quick ratio
1.37
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
20.3%
Gross margin
69.3%
Net margin
9.5%
Operating margin
13.3%
Return on assets
10.7%
Return on equity
41.5%
Return on invested capital
44.4%
Return on capital employed
34.3%
Return on sales
15.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PBYI stock price
How has the Puma Biotechnology stock price performed over time
Intraday
0.32%
1 week
-12.68%
1 month
7.64%
1 year
-37.37%
YTD
1.64%
QTD
1.64%
Financial performance
How have Puma Biotechnology's revenue and profit performed over time
Revenue
$243.57M
Gross profit
$168.76M
Operating income
$32.4M
Net income
$23.24M
Gross margin
69.3%
Net margin
9.5%
The net income has soared by 167% from the previous quarter
Puma Biotechnology's net margin has surged by 138% QoQ
The operating income has soared by 71% from the previous quarter and by 16% YoY
The operating margin has soared by 55% from the previous quarter and by 9% YoY
Growth
What is Puma Biotechnology's growth rate over time
Valuation
What is Puma Biotechnology stock price valuation
P/E
6.46
P/B
2.14
P/S
0.62
EV/EBIT
4.53
EV/EBITDA
3.47
EV/Sales
0.7
PBYI's EPS has surged by 153% since the previous quarter
The P/E is 46% lower than the last 4 quarters average of 12.0
Puma Biotechnology's equity has surged by 83% YoY and by 47% QoQ
PBYI's P/B is 39% lower than its last 4 quarters average of 3.5
PBYI's P/S is 38% below its 5-year quarterly average of 1.0 and 23% below its last 4 quarters average of 0.8
The revenue has grown by 11% from the previous quarter and by 6% YoY
Efficiency
How efficient is Puma Biotechnology business performance
PBYI's ROIC has soared by 196% YoY and by 74% QoQ
The ROA has soared by 161% QoQ
Puma Biotechnology's ROE has soared by 128% from the previous quarter
PBYI's return on sales has surged by 99% year-on-year and by 45% since the previous quarter
Dividends
What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PBYI.
Financial health
How did Puma Biotechnology financials performed over time
The total assets is 48% more than the total liabilities
The company's current ratio fell by 24% YoY but it rose by 8% QoQ
Puma Biotechnology's quick ratio has decreased by 19% YoY but it has increased by 14% from the previous quarter
Puma Biotechnology's debt is 21% higher than its equity
Puma Biotechnology's equity has surged by 83% YoY and by 47% QoQ
Puma Biotechnology's debt to equity has shrunk by 58% YoY and by 40% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.